

Grading: Stomatitis

Preferred Terms Included & Related NCI CTCAE v4.0 Terms

Preferred Term <i>(Listed in alphabetical order)</i>	CTCAE					
Aphthous stomatitis	Not listed in CTCAE	CTCAE Term or General Guideline used for grading was at the discretion of the investigators				
Glossitis						
Mouth ulceration						
Mucosal inflammation						
Stomatitis						
	CTCAE Term	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
	Mucositis oral	• Asymptomatic or mild symptoms; intervention not indicated	• Moderate pain; not interfering with oral intake; modified diet indicated	• Severe pain; interfering with oral intake	• Life-threatening consequences; urgent intervention indicated	• Death
	CTCAE	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
	General Guideline	• Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated	• Moderate; minimal, local or noninvasive intervention indicated; limiting age appropriate instrumental ADL	• Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL	• Life-threatening consequences; urgent intervention indicated	• Death related to AE

Dose Adjustments for DTC

Management of Stomatitis – Dose Adjustment

- Dose adjustment for management of lenvatinib toxicity, including stomatitis, was done in accordance with the following instructions:

Treatment-Related Toxicity ^a	Management	Dose adjustment
Grade 1	Treatment was continued	No change
Grade 2 – tolerable ^b	Treatment was continued	No change
Grade 2 – intolerable ^b	Treatment was interrupted ^c <ul style="list-style-type: none">• until resolved to Grade 0–1 or baseline	One-level dose reduction
Grade 3	Treatment was interrupted ^c <ul style="list-style-type: none">• until resolved to Grade 0–1 or baseline	One-level dose reduction
Grade 4	Lenvatinib was discontinued	

- Dose reductions occurred in succession based on the previous dose level
 - Once the dose was reduced, it was not increased at a later date

Recommended dose	First dosage reduction to	Second dosage reduction to	Third dosage reduction to	Fourth dosage reduction to
24 mg once daily	20 mg once daily	14 mg once daily	10 mg once daily	Discussed with Sponsor

^a. NCI CTCAE, version 4.0.
^b. Grade 2 toxicities were determined to be tolerable or intolerable by both the patient and investigator.
^c. An interruption of lenvatinib for more than 28 days (due to treatment-related toxicities) required a discussion with the sponsor before treatment was resumed.